Business
Notice of results and investor briefing
Notice of results and investor briefing.
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9607O EKF Diagnostics Holdings PLC 13 August 2014 \n \n\n \nEKF Diagnostics Holdings plc\n(\"EKF\", the \"Company\")\n \nNotice of results and investor briefing\n \nEKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, will be reporting its interim results for the six months ended 30 June 2014 on Monday 15 September 2014.\n \nAnalyst briefing\nJulian Baines (CEO) and Paul Foulger (FD) will be hosting a briefing for analysts on Monday 15 September 2014 at 10.00am at the London Capital Club, 15 Abchurch Lane, EC4N 7BW.\n \nInvestor briefing\nThe management team will also be presenting the Company's financial and operational results for investors on the evening of Wednesday 17 September 2014. The event is open to all investors and will be held at Rocket, 6, Adam's Court, Old Broad Street, EC2N 1DX, from 16:30 for a 16:45 start.\n \nTo register to attend the analyst briefing or investor briefing, please contact Walbrook PR (details below).\n \n \nEnquiries:\n\n\n\n\n \n\n\n \n\n\n\n\nWalbrook PR Limited \n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\nMob: 07980 541 893\n\n\n\n\nLianne Cawthorne\n\n\nMob: 07584 391 303\n\n\n\n\n \n \nAbout EKF Diagnostics Holdings plc - www.ekfdiagnostics.com\n \nEKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.\n \nThe Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lac...